Latanoprostene Bunod

Summary

Latanoprostene Bunod (CHEMBL2364612) is an approved small molecule (ATC S01EE06) targeting PTGFR; indicated across 3 conditions including open-angle glaucoma and ocular hypertension.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01EE06
• Targets: 1 (PTGFR)
• Indications: 3 conditions
• Clinical trials: 8
• Chemistry: 507.6 Da · C27H41NO8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2364612
Name	Latanoprostene Bunod
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	11156438
ATC	S01EE06
Molecular formula	C27H41NO8
Molecular weight	507.6
InChIKey	LOVMMUBRQUFEAH-UIEAZXIASA-N

SMILES: C1[C@H]([C@@H]([C@H]([C@H]1O)C/C=C\CCCC(=O)OCCCCO[N+](=O)[O-])CC[C@H](CCC2=CC=CC=C2)O)O

IUPAC name: 4-nitrooxybutyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate

Also known as: Latanoprostene bunod, Latanoprosteno bunod, NCX 116, NCX-116, NCX116, PF-3187207, Vyzulta, Vesneo, LATANOPROSTENE BUNOD, latanoprostene bunod

Patent coverage: 184 distinct patent families (517 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PTGFR	FP receptor	Agonist	8.6	0%	P43088

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prostaglandin G/H synthase 1.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): PTGFR.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Prostanoid ligand receptors	1	PTGFR
G alpha (q) signalling events	1	PTGFR

Dominant GO biological processes

GO term	Targets
inflammatory response	1
G protein-coupled receptor signaling pathway	1
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1
positive regulation of cytosolic calcium ion concentration	1
parturition	1
positive regulation of cell population proliferation	1
positive regulation of gene expression	1
response to estradiol	1
response to lipopolysaccharide	1
negative regulation of apoptotic process	1
cellular response to prostaglandin D stimulus	1
signal transduction	1
response to lipid	1

Indications & clinical

Indications

3 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
open-angle glaucoma	4	MONDO:0005338	EFO:0004190
ocular hypertension	4	MONDO:0006875	EFO:1001069
glaucoma	4	MONDO:0005041	MONDO:0005041

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	2
PHASE4	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04140279	PHASE4	WITHDRAWN	A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension
NCT01749904	PHASE3	COMPLETED	Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT01749930	PHASE3	COMPLETED	Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT01895972	PHASE3	COMPLETED	Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT
NCT01223378	PHASE2	COMPLETED	Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension
NCT01707381	PHASE2	COMPLETED	BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT01895985	PHASE1	COMPLETED	Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers
NCT03931317	Not specified	COMPLETED	Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

13 molecules share ≥1 primary target. Top 13 by shared-target count:

Molecule	Source	Status	Shared targets
DINOPROST	ChEMBL + PubChem	Phase 4 (approved)	PTGFR
DINOPROSTONE	ChEMBL + PubChem	Phase 4 (approved)	PTGFR
LAROPIPRANT	ChEMBL	Phase 4 (approved)	PTGFR
SEPETAPROST	ChEMBL	Phase 3	PTGFR
CLOPROSTENOL	ChEMBL + PubChem	Phase 2 (approved)	PTGFR
EBOPIPRANT	ChEMBL	Phase 2	PTGFR
FLUPROSTENOL	ChEMBL	Phase 2	PTGFR
Belzutifan	PubChem	Approved	PTGFR
Bimatoprost	PubChem	Approved	PTGFR
Grapiprant	PubChem	Approved	PTGFR
Latanoprost	PubChem	Approved	PTGFR
Nitroglycerin	PubChem	Approved	PTGFR
Tafluprost	PubChem	Approved	PTGFR